News
Please, enter cell line, author or any other phrase or word you would like to search for.
Interim Report 1 2023/24
During this past summer quarter, we made it our most prosperous Q1 quarter to date, characterized by sustained growth.
Notice that Interim Report 1 2023/24 will be published on September 20, 2023
Phase Holographic Imaging announces that the date for publication of Interim Report 1 2023/24 is September 20, 2023.
PHI AB annual general meeting moved to 27 October 2023
The PHI AB board has decided to move the company’s annual general meeting from 12 October 2023 to 27 October 2023.
BioStock: PHI links up with two regenerative medicine networks
BioStock contacted CEO Patrik Eschricht to learn more about the company’s future strategies in regenerative medicine and the pivot toward the clinical market.
PHI Strengthens Commitment to Regenerative Medicine through ARM and ATMP Sweden Membership
PHI becomes a member of the leading international advocacy organization Alliance for Regenerative Medicine (ARM) as well as the national ATMP Sweden network to advocate for QPI technology for standard cell quality control in regenerative medicine.
BioStock: PHI charts a bold course to impact regenerative medicine
BioStock contacted CEO Patrik Eschricht to delve into the year-end report’s highlights and shed light on the company’s vision and initiatives.
BioStock: The five best life science stocks of the first half-year
PHI is proud to be highlighted as one of the top 5 best-performing Swedish life science stocks in the first half of 2023.
European Patent Office intends to grant PHI patent on synthetic antibodies
PHI AB announces today that the European Patent Office (EPO) intends to grant a patent on synthetic antibodies.
BioStock: PHI’s CEO reflects on global roadshow success
BioStock contacted CEO Patrik Eschricht to learn about the team’s achievements on their global roadshow this early summer.
Interim Report 4 2022/23
Sales continue to grow, and the year ended up with the highest turnover for a year in PHI, so far.